BCL6公司
荧光原位杂交
弥漫性大B细胞淋巴瘤
淋巴瘤
分类器(UML)
肿瘤科
医学
免疫组织化学
计算生物学
内科学
病理
生物
计算机科学
B细胞
基因
遗传学
人工智能
免疫学
生发中心
抗体
染色体
作者
Vanesa‐Sindi Ivanova,Visar Vela,Stefan Dirnhofer,Michaël Dobbie,Frank Stenner,Jan Knoblich,Alexandar Tzankov,Thomas Menter
出处
期刊:Pathobiology
[S. Karger AG]
日期:2023-12-21
摘要
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity. Lately, several algorithms achieving therapeutically and prognostically relevant DLBCL subclassification have been published.A cohort of 74 routine DLBCL cases was broadly characterized by immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) of the BCL2, BCL6 and MYC loci, and comprehensive high throughput sequencing (HTS). Based on the genetic alterations found, cases were reclassified using two probabilistic tools - LymphGen and Two-step classifier, allowing for comparison of the two models.Hans and Tally's overall IHC-based subclassification success rate was 96% and 82%, respectively. HTS and FISH data allowed the LymphGen algorithm to successfully classify 11/55 cases, (1 - BN2, 7 - EZB, 1 - MCD, and 2 - genetically composite EZB/N1). The total subclassification rate was 20%. On the other hand, the Two-step classifier categorized 36/55 cases, with 65.5% success (9 - BN2, 12 - EZB, 9 - MCD, 2 - N1, and 4 - ST2). Clinical correlations highlighted MCD as an aggressive subtype associated with higher relapse and mortality.The Two-step algorithm has a better success rate at subclassifying DLBCL cases based on genetic differences. Further improvement of the classifiers is required to increase the number of classifiable cases and thus prove their applicability in routine diagnostics.
科研通智能强力驱动
Strongly Powered by AbleSci AI